Frexalimab compared to teriflunomide in participants with relapsing forms of MS

To assess the efficacy of frexalimab compared to a daily dose of 14 mg teriflunomide measured by ARR in participants with relapsing forms of multiple sclerosis (MS)

• Adults 18-55 years of age
• Diagnosed with Relapsing Multiple Sclerosis (RMS) according to the 2017 revision of the McDonald diagnostic criteria
• EDSS score ≤5.5 at the first visit
• Have at least 1 of the following:

≥1 documented relapse within the previous year OR

≥2 documented relapses within the previous 2 years, OR

≥1 documented Gd enhancing lesion on an MRI scan within the previous year

Participation in the study will include:

Random assignment to one of two study arms:

• Experimental (Fexalimab): Participants will receive Frexalimab infusion given intravenously (IV) on day 1 and every 4 weeks thereafter and placebo tablet once daily given orally
• Active Comparator (Teriflunomide): Participants will receive a 14mg teriflunomide tablet once daily given orally and placebo infusion given intravenously (IV) on day 1 and every 4 weeks thereafter.